- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01394289
Biological Standardization of Lolium Perenne Allergen Extract
Biological Standardization of Lolium Perenne Allergen Extract to Determine the Biological Activity in HEP Units
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Salamanca, Spain, 37007
- Hospital Universitario de Salamanca
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
- Subject can be male or female of any race and ethnic group.
- Age > 18 years and < 50 years at the study inclusion day.
- Positive skin prick test with a standardized commercially available preparation of Lolium perenne allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm and at least the size of the positive control. Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
- A positive test for specific IgE to Lolium perenne (CAP-RAST ≥ 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
- Allergic symptoms during the pollen season of Lolium perenne.
- Mean of the forearm major diameters of the wheals provoked by histamine dihydrochloride (10 mg/ml) ≥ 3 mm.
Exclusion Criteria:
- Immunotherapy in the past 5 years with an allergen preparation known to interfere with the allergen to be tested (e.g., grass group extracts).
- Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1
- Treatment with any of the following medications: tricyclic or tetracyclic antidepressants, β-blockers or corticosteroids (> 10 mg/day of prednisone or equivalent).
- Pregnancy.
- Dermographism affecting the skin area at the test site at either study visit.
- Atopic dermatitis affecting the skin area at the test site at either study visit.
- Urticaria affecting the skin area at the test site at either study visit.
- Participation in another clinical trial within the last month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Biological/Vaccine: Lolium allergen extract
Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.
This test will be referred to as the Titrated Skin Prick test.
|
This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines. Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.
Time Frame: 30 minutes per subject
|
30 minutes per subject
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: María José Gómez, Laboratorios Leti, S.L.U
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 6041-PR-PRI-182
- 2010-023949-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy to Grass Pollen
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.CompletedAllergy to Grass Pollen (Dactylis Glomerata)Spain
-
Laboratorios Leti, S.L.CompletedAllergy to Grass Pollen (Secale Cereale)Spain
-
Aston UniversityNational Pollen and Aerobiology Unit, WorcesterCompletedGrass Pollen Ocular AllergyUnited Kingdom
-
University of ZurichAlleCureCompletedRhinoconjunctivitis Due to Grass Pollen AllergySwitzerland
-
MacroArray Diagnostics GmbHCompletedCat Allergy | Grass Pollen Allergy | Birch Pollen Allergy | House Dust Mite Allergy | Bee Venom Allergy | Vespid Venom AllergyAustria
-
Laboratorios Leti, S.L.Completed
-
Biomay AGCompletedGrass Pollen AllergyAustria, Belgium, Denmark, Germany, Netherlands, Slovenia
-
Biomay AGCompletedGrass Pollen AllergyAustria
-
Allergopharma GmbH & Co. KGCompletedGrass Pollen AllergyGermany
Clinical Trials on Lolium allergen extract
-
Gachon University Gil Medical CenterThermo Fisher Scientific, IncCompletedAllergic RhinitisKorea, Republic of
-
Inmunotek S.L.CompletedImmune System DiseasesSpain
-
GlaxoSmithKlineCompleted
-
Roxall MedizinUnknown
-
National Institute of Allergy and Infectious Diseases...Inner-City Asthma ConsortiumTerminated
-
Roxall MedizinUnknownAllergic Rhinitis | Allergic ConjunctivitisGermany
-
University Hospital, Strasbourg, FranceCompleted
-
Laboratorios Leti, S.L.CompletedSeasonal Allergic RhinitisSpain, Hungary